The role of ubiquitin modification in the regulation of p53

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 1, 2014, Pages 137-149

  Hock, Andreas K ^a   Vousden, Karen H ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

MDM2; MDMX; P53

Indexed keywords

BMI1 PROTEIN; GANKYRIN; MICRORNA 1; PROTEASOME; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CELL CYCLE ARREST; CELL DIVISION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME MODIFICATION; FEEDBACK SYSTEM; GENE MUTATION; HUMAN; HUMAN CELL; NEDDYLATION; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TARGETING; QUALITY CONTROL; REVIEW; SENESCENCE; TRANSACTIVATION; UBIQUITINATION;

EID: 84890200628     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.05.022     Document Type: Review

References (270)

1. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 2001, 70:503-533.
2. David Y., Ternette N., Edelmann M.J., Ziv T., Gayer B., Sertchook R., Dadon Y., Kessler B.M., Navon A. E3 ligases determine ubiquitination site and conjugate type by enforcing specificity on E2 enzymes. J. Biol. Chem. 2011, 286:44104-44115.
3. Thrower J.S., Hoffman L., Rechsteiner M., Pickart C.M. Recognition of the polyubiquitin proteolytic signal. EMBO J. 2000, 19:94-102.
4. Tokunaga F., Sakata S., Saeki Y., Satomi Y., Kirisako T., Kamei K., Nakagawa T., Kato M., Murata S., Yamaoka S., Yamamoto M., Akira S., Takao T., Tanaka K., Iwai K. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat. Cell Biol. 2009, 11:123-132.
5. Hoege C., Pfander B., Moldovan G.L., Pyrowolakis G., Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 2002, 419:135-141.
6. Lauwers E., Jacob C., Andre B. K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway. J. Cell Biol. 2009, 185:493-502.
7. Hurley J.H., Stenmark H. Molecular mechanisms of ubiquitin-dependent membrane traffic. Annu. Rev. Biophys. 2011, 40:119-142.
8. Kulathu Y., Komander D. Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat. Rev. Mol. Cell Biol. 2012, 13:508-523.
9. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
10. Sola S., Morgado A.L., Rodrigues C.M. Death receptors and mitochondria: two prime triggers of neural apoptosis and differentiation. Biochim. Biophys. Acta 2013, 1830:2160-2166.
11. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991, 253:49-53.
12. Hainaut P., Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 1999, vol. 77:81-137. Elsevier.
13. Gu B., Zhu W.G. Surf the post-translational modification network of p53 regulation. Int. J. Biol. Sci. 2012, 8:672-684.
14. Tsvetkov P., Reuven N., Shaul Y. Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ. 2010, 17:103-108.
15. Loewer A., Batchelor E., Gaglia G., Lahav G. Basal dynamics of p53 reveal transcriptionally attenuated pulses in cycling cells. Cell 2010, 142:89-100.
16. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378:206-208.
17. Montes de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378:203-206.
18. Parant J., Chavez-Reyes A., Little N.A., Yan W., Reinke V., Jochemsen A.G., Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 2001, 29:92-95.
19. Steinman H.A., Hoover K.M., Keeler M.L., Sands A.T., Jones S.N. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development. Oncogene 2005, 24:7935-7940.
20. De Clercq S., Gembarska A., Denecker G., Maetens M., Naessens M., Haigh K., Haigh J.J., Marine J.C. Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo. Mol. Cell. Biol. 2010, 30:5394-5405.
21. Grier J.D., Xiong S., Elizondo-Fraire A.C., Parant J.M., Lozano G. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol. Cell. Biol. 2006, 26:192-198.
22. Wadgaonkar R., Collins T. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression. J. Biol. Chem. 1999, 274:13760-13767.
23. Kobet E., Zeng X., Zhu Y., Keller D., Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12547-12552.
24. Ito A., Kawaguchi Y., Lai C.-H., Kovacs J.J., Higashimoto Y., Appella E., Yao T.-P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 2002, 21:6236-6245.
25. Sasaki M., Nie L., Maki C.G. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J. Biol. Chem. 2007, 282:14626-14634.
26. Cross B., Chen L., Cheng Q., Li B., Yuan Z.M., Chen J. Inhibition of p53 DNA binding function by the MDM2 protein acidic domain. J. Biol. Chem. 2011, 286:16018-16029.
27. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
28. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
29. Wang X., Wang J., Jiang X. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J. Biol. Chem. 2011, 286:23725-23734.
30. Pant V., Xiong S., Iwakuma T., Quintas-Cardama A., Lozano G. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:11995-12000.
31. Huang L., Yan Z., Liao X., Li Y., Yang J., Wang Z.G., Zuo Y., Kawai H., Shadfan M., Ganapathy S., Yuan Z.M. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12001-12006.
32. Rodriguez M.S., Desterro J.M., Lain S., Lane D.P., Hay R.T. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 2000, 20:8458-8467.
33. Poyurovsky M.V., Priest C., Kentsis A., Borden K.L., Pan Z.Q., Pavletich N., Prives C. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 2007, 26:90-101.
34. Uldrijan S., Pannekoek W.J., Vousden K.H. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J. 2007, 26:102-112.
35. Dolezelova P., Cetkovska K., Vousden K.H., Uldrijan S. Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers. Cell Cycle 2012, 11:953-962.
36. Dou H., Buetow L., Sibbet G.J., Cameron K., Huang D.T. BIRC7-E2 ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer by a RING dimer. Nat. Struct. Mol. Biol. 2012, 19:876-883.
37. Kulikov R., Letienne J., Kaur M., Grossman S.R., Arts J., Blattner C. Mdm2 facilitates the association of p53 with the proteasome. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10038-10043.
38. Gajjar M., Candeias M.M., Malbert-Colas L., Mazars A., Fujita J., Olivares-Illana V., Fahraeus R. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer cell 2012, 21:25-35.
39. Clegg H.V., Itahana Y., Itahana K., Ramalingam S., Zhang Y. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction. PLoS One 2012, 7:e38212.
40. Li M., Brooks C.L., Wu-Baer F., Chen D., Baer R., Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003, 302:1972-1975.
41. Di Conza G., Mancini F., Buttarelli M., Pontecorvi A., Trimarchi F., Moretti F. MDM4 enhances p53 stability by promoting an active conformation of the protein upon DNA damage. Cell Cycle 2012, 11:749-760.
42. Marchenko N.D., Wolff S., Erster S., Becker K., Moll U.M. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J. 2007, 26:923-934.
43. Tasdemir E., Maiuri M.C., Galluzzi L., Vitale I., Djavaheri-Mergny M., D'Amelio M., Criollo A., Morselli E., Zhu C., Harper F., Nannmark U., Samara C., Pinton P., Vicencio J.M., Carnuccio R., Moll U.M., Madeo F., Paterlini-Brechot P., Rizzuto R., Szabadkai G., Pierron G., Blomgren K., Tavernarakis N., Codogno P., Cecconi F., Kroemer G. Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol. 2008, 10:676-687.
44. Jiang P., Du W., Wang X., Mancuso A., Gao X., Wu M., Yang X. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 2011, 13:310-316.
45. Nikolaev A.Y., Li M., Puskas N., Qin J., Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003, 112:29-40.
46. Pei X.H., Bai F., Li Z.J., Smith M.D., Whitewolf G., Jin R., Xiong Y. Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis. Cancer Res. 2011, 71:2969-2977.
47. Xirodimas D.P., Saville M.K., Bourdon J.C., Hay R.T., Lane D.P. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004, 118:83-97.
48. Liu G., Xirodimas D.P. NUB1 promotes cytoplasmic localization of p53 through cooperation of the NEDD8 and ubiquitin pathways. Oncogene 2010, 29:2252-2261.
49. Singh R.K., Iyappan S., Scheffner M. Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2. J. Biol. Chem. 2007, 282:10901-10907.
50. Abida W.M., Nikolaev A., Zhao W., Zhang W., Gu W. FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J. Biol. Chem. 2007, 282:1797-1804.
51. Stehmeier P., Muller S. Regulation of p53 family members by the ubiquitin-like SUMO system. DNA Repair (Amst) 2009, 8:491-498.
52. Chen L., Chen J. MDM2-ARF complex regulates p53 sumoylation. Oncogene 2003, 22:5348-5357.
53. Li T., Santockyte R., Shen R.F., Tekle E., Wang G., Yang D.C., Chock P.B. Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways. J. Biol. Chem. 2006, 281:36221-36227.
54. Stindt M.H., Carter S., Vigneron A.M., Ryan K.M., Vousden K.H. MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. Cell Cycle 2011, 10:3176-3188.
55. Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., Scheffner M., Del Sal G. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 1999, 18:6462-6471.
56. Kahyo T., Nishida T., Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol. Cell 2001, 8:713-718.
57. Carter S., Bischof O., Dejean A., Vousden K.H. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat. Cell Biol. 2007, 9:428-435.
58. Carter S., Vousden K.H. p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 2008, 7:2519-2528.
59. Muller S., Berger M., Lehembre F., Seeler J.S., Haupt Y., Dejean A. c-Jun and p53 activity is modulated by SUMO-1 modification. J. Biol. Chem. 2000, 275:13321-13329.
60. Kwek S.S., Derry J., Tyner A.L., Shen Z., Gudkov A.V. Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene 2001, 20:2587-2599.
61. Itahana K., Mao H., Jin A., Itahana Y., Clegg H.V., Lindstrom M.S., Bhat K.P., Godfrey V.L., Evan G.I., Zhang Y. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer cell 2007, 12:355-366.
62. Gu J.J., Kawai H., Nie L.G., Kitao H., Wiederschain D., Jochemsen A.G., Parant J., Lozano G., Yuan Z.M. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem. 2002, 277:19251-19254.
63. Migliorini D., Danovi D., Colombo E., Carbone R., Pelicci P.G., Marine J.C. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. J. Biol. Chem. 2002, 277:7318-7323.
64. Garcia D., Warr M.R., Martins C.P., Brown Swigart L., Passegue E., Evan G.I. Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes Dev. 2011, 25:1746-1757.
65. Ringshausen I., O'Shea C.C., Finch A.J., Swigart L.B., Evan G.I. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer cell 2006, 10:501-514.
66. Momand J., Jung D., Wilczynski S., Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998, 26:3453-3459.
67. Onel K., Cordon-Cardo C. MDM2 and prognosis. Mol. Cancer Res. 2004, 2:1-8.
68. Danovi D., Meulmeester E., Pasini D., Migliorini D., Capra M., Frenk R., de Graaf P., Francoz S., Gasparini P., Gobbi A., Helin K., Pelicci P.G., Jochemsen A.G., Marine J.C. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell. Biol. 2004, 24:5835-5843.
69. Gembarska A., Luciani F., Fedele C., Russell E.A., Dewaele M., Villar S., Zwolinska A., Haupt S., de Lange J., Yip D., Goydos J., Haigh J.J., Haupt Y., Larue L., Jochemsen A., Shi H., Moriceau G., Lo R.S., Ghanem G., Shackleton M., Bernal F., Marine J.C. MDM4 is a key therapeutic target in cutaneous melanoma. Nat. Med. 2012, 1239-1247.
70. Zhang X., Zhang Z., Cheng J., Li M., Wang W., Xu W., Wang H., Zhang R. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53. J. Biol. Chem. 2012, 287:30468-30476.
71. Guo L., Liew H.P., Camus S., Goh A.M., Chee L.L., Lunny D.P., Lane E.B., Lane D.P. Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish. Oncogene 2013, (in press). 10.1038/onc.2012.409.
72. Phillips A., Teunisse A., Lam S., Lodder K., Darley M., Emaduddin M., Wolf A., Richter J., de Lange J., Verlaan-de Vries M., Lenos K., Bohnke A., Bartel F., Blaydes J.P., Jochemsen A.G. HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity. J. Biol. Chem. 2010, 285:29111-29127.
73. Li B., Cheng Q., Li Z., Chen J. p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors. Cell Cycle 2010, 9:1411-1420.
74. Gilkes D.M., Pan Y., Coppola D., Yeatman T., Reuther G.W., Chen J. Regulation of MDMX expression by mitogenic signaling. Mol. Cell. Biol. 2008, 28:1999-2010.
75. Biderman L., Poyurovsky M.V., Assia Y., Manley J.L., Prives C. MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress. Mol. Cell. Biol. 2012, 32:1214-1225.
76. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., Bargonetti J., Bartel F., Taubert H., Wuerl P., Onel K., Yip L., Hwang S.J., Strong L.C., Lozano G., Levine A.J. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
77. Jeyaraj S., O'Brien D.M., Chandler D.S. MDM2 and MDM4 splicing: an integral part of the cancer spliceosome. Front. Biosci. 2009, 14:2647-2656.
78. Linke K., Mace P.D., Smith C.A., Vaux D.L., Silke J., Day C.L. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 2008, 15:841-848.
79. Xirodimas D.P., Chisholm J., Desterro J.M., Lane D.P., Hay R.T. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett. 2002, 528:207-211.
80. Watson I.R., Li B.K., Roche O., Blanch A., Ohh M., Irwin M.S. Chemotherapy induces NEDP1-mediated destabilization of MDM2. Oncogene 2010, 29:297-304.
81. Pan Y., Chen J. Modification of MDMX by sumoylation. Biochem. Biophys. Res. Commun. 2005, 332:702-709.
82. Meek D.W., Hupp T.R. The regulation of MDM2 by multisite phosphorylation-opportunities for molecular-based intervention to target tumours?. Semin. Cancer Biol. 2010, 20:19-28.
83. Waning D.L., Lehman J.A., Batuello C.N., Mayo L.D. Controlling the Mdm2-Mdmx-p53 circuit. Pharmaceuticals (Basel) 2010, 3:1576-1593.
84. Wade M., Wang Y.V., Wahl G.M. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010, 20:299-309.
85. Chen J. The roles of MDM2 and MDMX phosphorylation in stress signaling to p53. Genes Cancer 2012, 3:274-282.
86. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91:325-334.
87. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998, 281:1674-1677.
88. Chehab N.H., Malikzay A., Appel M., Halazonetis T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 2000, 14:278-288.
89. Shieh S.Y., Ahn J., Tamai K., Taya Y., Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 2000, 14:289-300.
90. Blattner C., Tobiasch E., Litfen M., Rahmsdorf H.J., Herrlich P. DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 1999, 18:1723-1732.
91. Dumaz N., Meek D.W. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 1999, 18:7002-7010.
92. Yamauchi M., Suzuki K., Kodama S., Watanabe M. Stabilization of alanine substituted p53 protein at Ser15, Thr18, and Ser20 in response to ionizing radiation. Biochem. Biophys. Res. Commun. 2004, 323:906-911.
93. Chao C., Hergenhahn M., Kaeser M.D., Wu Z., Saito S., Iggo R., Hollstein M., Appella E., Xu Y. Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J. Biol. Chem. 2003, 278:41028-41033.
94. Sluss H.K., Armata H., Gallant J., Jones S.N. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol. Cell. Biol. 2004, 24:976-984.
95. MacPherson D., Kim J., Kim T., Rhee B.K., Van Oostrom C.T., DiTullio R.A., Venere M., Halazonetis T.D., Bronson R., De Vries A., Fleming M., Jacks T. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J. 2004, 23:3689-3699.
96. Wu Z., Earle J., Saito S., Anderson C.W., Appella E., Xu Y. Mutation of mouse p53 Ser23 and the response to DNA damage. Mol. Cell. Biol. 2002, 22:2441-2449.
97. Chao C., Herr D., Chun J., Xu Y. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J. 2006, 25:2615-2622.
98. Lu H., Taya Y., Ikeda M., Levine A.J. Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6399-6402.
99. Huang C., Ma W.Y., Maxiner A., Sun Y., Dong Z. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J. Biol. Chem. 1999, 274:12229-12235.
100. Hoogervorst E.M., Bruins W., Zwart E., van Oostrom C.T., van den Aardweg G.J., Beems R.B., van den Berg J., Jacks T., van Steeg H., de Vries A. Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas. Cancer Res. 2005, 65:3610-3616.
101. Bruins W., Zwart E., Attardi L.D., Iwakuma T., Hoogervorst E.M., Beems R.B., Miranda B., van Oostrom C.T., van den Berg J., van den Aardweg G.J., Lozano G., van Steeg H., Jacks T., de Vries A. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol. Cell. Biol. 2004, 24:8884-8894.
102. Mayo L.D., Turchi J.J., Berberich S.J. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 1997, 57:5013-5016.
103. Cheng Q., Chen L., Li Z., Lane W.S., Chen J. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J. 2009, 28:3857-3867.
104. Cheng Q., Cross B., Li B., Chen L., Li Z., Chen J. Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage. Mol. Cell. Biol. 2011, 31:4951-4963.
105. Cheng Q., Chen J. The phenotype of MDM2 auto-degradation after DNA damage is due to epitope masking by phosphorylation. Cell Cycle 2011, 10:1162-1166.
106. Gannon H.S., Woda B.A., Jones S.N. ATM phosphorylation of Mdm2 Ser394 regulates the amplitude and duration of the DNA damage response in mice. Cancer cell 2012, 21:668-679.
107. Pereg Y., Lam S., Teunisse A., Biton S., Meulmeester E., Mittelman L., Buscemi G., Okamoto K., Taya Y., Shiloh Y., Jochemsen A.G. Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. Mol. Cell. Biol. 2006, 26:6819-6831.
108. LeBron C., Chen L., Gilkes D.M., Chen J. Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J. 2006, 25:1196-1206.
109. Pereg Y., Shkedy D., de Graaf P., Meulmeester E., Edelson-Averbukh M., Salek M., Biton S., Teunisse A.F., Lehmann W.D., Jochemsen A.G., Shiloh Y. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5056-5061.
110. Okamoto K., Kashima K., Pereg Y., Ishida M., Yamazaki S., Nota A., Teunisse A., Migliorini D., Kitabayashi I., Marine J.C., Prives C., Shiloh Y., Jochemsen A.G., Taya Y. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol. Cell. Biol. 2005, 25:9608-9620.
111. Wang Y.V., Leblanc M., Wade M., Jochemsen A.G., Wahl G.M. Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer cell 2009, 16:33-43.
112. Lu X., Ma O., Nguyen T.A., Jones S.N., Oren M., Donehower L.A. The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer cell 2007, 12:342-354.
113. Zhang X., Lin L., Guo H., Yang J., Jones S.N., Jochemsen A., Lu X. Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response. Cancer Res. 2009, 69:7960-7968.
114. Buss M.C., Read T.A., Schniederjan M.J., Gandhi K., Castellino R.C. HDM2 promotes WIP1-mediated medulloblastoma growth. Neuro Oncol. 2012, 14:440-458.
115. Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006, 444:629-632.
116. Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W., Dutta S., Appella E., Gozani O. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol. Cell 2007, 27:636-646.
117. Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F., Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G. PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53. Nat. Struct. Mol. Biol. 2012, 19:916-924.
118. Li M., Luo J., Brooks C.L., Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 2002, 277:50607-50611.
119. Zheng H., You H., Zhou X.Z., Murray S.A., Uchida T., Wulf G., Gu L., Tang X., Lu K.P., Xiao Z.X. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 2002, 419:849-853.
120. Yang W.H., Kim J.E., Nam H.W., Ju J.W., Kim H.S., Kim Y.S., Cho J.W. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat. Cell Biol. 2006, 8:1074-1083.
121. Toledo F., Lee C.J., Krummel K.A., Rodewald L.W., Liu C.W., Wahl G.M. Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Mol. Cell. Biol. 2007, 27:1425-1432.
122. Lu X. Tied up in loops: positive and negative autoregulation of p53. Cold Spring Harb. Perspect. Biol. 2010, 2:a000984.
123. Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 1993, 12:461-468.
124. Leng R.P., Lin Y., Ma W., Wu H., Lemmers B., Chung S., Parant J.M., Lozano G., Hakem R., Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003, 112:779-791.
125. Dornan D., Wertz I., Shimizu H., Arnott D., Frantz G.D., Dowd P., O'Rourke K., Koeppen H., Dixit V.M. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004, 429:86-92.
126. Oliver T.G., Meylan E., Chang G.P., Xue W., Burke J.R., Humpton T.J., Hubbard D., Bhutkar A., Jacks T. Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol. Cell 2011, 43:57-71.
127. Palmero I., Pantoja C., Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 1998, 395:125-126.
128. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998, 12:2424-2433.
129. Bates S., Phillips A.C., Clark P.A., Stott F., Peters G., Ludwig R.L., Vousden K.H. p14ARF links the tumour suppressors RB and p53. Nature 1998, 395:124-125.
130. Damalas A., Ben-Ze'ev A., Simcha I., Shtutman M., Leal J.F., Zhurinsky J., Geiger B., Oren M. Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J. 1999, 18:3054-3063.
131. Li Z., Hou J., Sun L., Wen T., Wang L., Zhao X., Xie Q., Zhang S.Q. NMI mediates transcription-independent ARF regulation in response to cellular stresses. Mol. Biol. Cell 2012, 23:4635-4646.
132. Chen D., Shan J., Zhu W.G., Qin J., Gu W. Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature 2010, 464:624-627.
133. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 2006, 6:663-673.
134. Xirodimas D., Saville M.K., Edling C., Lane D.P., Lain S. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene 2001, 20:4972-4983.
135. Golomb L., Bublik D.R., Wilder S., Nevo R., Kiss V., Grabusic K., Volarevic S., Oren M. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol. Cell 2012, 45:222-232.
136. Tsoi H., Lau T.C., Tsang S.Y., Lau K.F., Chan H.Y. CAG expansion induces nucleolar stress in polyglutamine diseases. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:13428-13433.
137. Li H., Tsang C.K., Watkins M., Bertram P.G., Zheng X.F. Nutrient regulates Tor1 nuclear localization and association with rDNA promoter. Nature 2006, 442:1058-1061.
138. Deisenroth C., Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene 2010, 29:4253-4260.
139. Zhang Y., Lu H. Signaling to p53: ribosomal proteins find their way. Cancer cell 2009, 16:369-377.
140. Zhou X., Liao J.M., Liao W.J., Lu H. Scission of the p53-MDM2 loop by ribosomal proteins. Genes Cancer 2012, 3:298-310.
141. Dai M.S., Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 2004, 279:44475-44482.
142. Lohrum M.A., Ludwig R.L., Kubbutat M.H., Hanlon M., Vousden K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer cell 2003, 3:577-587.
143. Zhang Y., Wolf G.W., Bhat K., Jin A., Allio T., Burkhart W.A., Xiong Y. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 2003, 23:8902-8912.
144. Fumagalli S., Di Cara A., Neb-Gulati A., Natt F., Schwemberger S., Hall J., Babcock G.F., Bernardi R., Pandolfi P.P., Thomas G. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat. Cell Biol. 2009, 11:501-508.
145. Dai M.S., Zeng S.X., Jin Y., Sun X.X., David L., Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol. Cell. Biol. 2004, 24:7654-7668.
146. Ofir-Rosenfeld Y., Boggs K., Michael D., Kastan M.B., Oren M. Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol. Cell 2008, 32:180-189.
147. Chen D., Zhang Z., Li M., Wang W., Li Y., Rayburn E.R., Hill D.L., Wang H., Zhang R. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene 2007, 26:5029-5037.
148. Zhu Y., Poyurovsky M.V., Li Y., Biderman L., Stahl J., Jacq X., Prives C. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol. Cell 2009, 35:316-326.
149. Xiong X., Zhao Y., He H., Sun Y. Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator. Oncogene 2011, 30:1798-1811.
150. Zhou X., Hao Q., Liao J., Zhang Q., Lu H. Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene 2013, 32:388-396.
151. Zhang X., Wang W., Wang H., Wang M.H., Xu W., Zhang R. Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop. Oncogene 2013, 32:2782-2791.
152. Gilkes D.M., Chen L., Chen J. MDMX regulation of p53 response to ribosomal stress. EMBO J. 2006, 25:5614-5625.
153. Bursac S., Brdovcak M.C., Pfannkuchen M., Orsolic I., Golomb L., Zhu Y., Katz C., Daftuar L., Grabusic K., Vukelic I., Filic V., Oren M., Prives C., Volarevic S. Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:20467-20472.
154. Macias E., Jin A., Deisenroth C., Bhat K., Mao H., Lindstrom M.S., Zhang Y. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer cell 2010, 18:231-243.
155. Lindstrom M.S., Jin A., Deisenroth C., White Wolf G., Zhang Y. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol. Cell. Biol. 2007, 27:1056-1068.
156. Ma H., Pederson T. Depletion of the nucleolar protein nucleostemin causes G1 cell cycle arrest via the p53 pathway. Mol. Biol. Cell 2007, 18:2630-2635.
157. Sasaki M., Kawahara K., Nishio M., Mimori K., Kogo R., Hamada K., Itoh B., Wang J., Komatsu Y., Yang Y.R., Hikasa H., Horie Y., Yamashita T., Kamijo T., Zhang Y., Zhu Y., Prives C., Nakano T., Mak T.W., Sasaki T., Maehama T., Mori M., Suzuki A. Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nat. Med. 2011, 17:944-951.
158. Lee S., Kim J.Y., Kim Y.J., Seok K.O., Kim J.H., Chang Y.J., Kang H.Y., Park J.H. Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal stresses. Cell Death Differ. 2012, 19:1613-1622.
159. Kurki S., Peltonen K., Latonen L., Kiviharju T.M., Ojala P.M., Meek D., Laiho M. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer cell 2004, 5:465-475.
160. Horn H.F., Vousden K.H. Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway. Oncogene 2008, 27:5774-5784.
161. Dai M.S., Challagundla K.B., Sun X.X., Palam L.R., Zeng S.X., Wek R.C., Lu H. Physical and functional interaction between ribosomal protein L11 and the tumor suppressor ARF. J. Biol. Chem. 2012, 287:17120-17129.
162. Ma J., Martin J.D., Zhang H., Auger K.R., Ho T.F., Kirkpatrick R.B., Grooms M.H., Johanson K.O., Tummino P.J., Copeland R.A., Lai Z. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry 2006, 45:9238-9245.
163. Lee M.H., Lee S.W., Lee E.J., Choi S.J., Chung S.S., Lee J.I., Cho J.M., Seol J.H., Baek S.H., Kim K.I., Chiba T., Tanaka K., Bang O.S., Chung C.H. SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination. Nat. Cell Biol. 2006, 8:1424-1431.
164. Juven-Gershon T., Shifman O., Unger T., Elkeles A., Haupt Y., Oren M. The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol. Cell. Biol. 1998, 18:3974-3982.
165. Colaluca I.N., Tosoni D., Nuciforo P., Senic-Matuglia F., Galimberti V., Viale G., Pece S., Di Fiore P.P. NUMB controls p53 tumour suppressor activity. Nature 2008, 451:76-80.
166. Sczaniecka M., Gladstone K., Pettersson S., McLaren L., Huart A.S., Wallace M. MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism. J. Biol. Chem. 2012, 287:14052-14068.
167. Kurki S., Latonen L., Laiho M. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J. Cell Sci. 2003, 116:3917-3925.
168. Bernardi R., Scaglioni P.P., Bergmann S., Horn H.F., Vousden K.H., Pandolfi P.P. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat. Cell Biol. 2004, 6:665-672.
169. Chau J.F., Jia D., Wang Z., Liu Z., Hu Y., Zhang X., Jia H., Lai K.P., Leong W.F., Au B.J., Mishina Y., Chen Y.G., Biondi C., Robertson E., Xie D., Liu H., He L., Wang X., Yu Q., Li B. A crucial role for bone morphogenetic protein-Smad1 signalling in the DNA damage response. Nat. Commun. 2012, 3:836.
170. Pan D., Zhu Q., Conboy M.J., Conboy I.M., Luo K. SnoN activates p53 directly to regulate aging and tumorigenesis. Aging Cell 2012, 11:902-911.
171. Lew Q.J., Chia Y.L., Chu K.L., Lam Y.T., Gurumurthy M., Xu S., Lam K.P., Cheong N., Chao S.H. Identification of HEXIM1 as a positive regulator of p53. J. Biol. Chem. 2012, 287:36443-36454.
172. Bae S., Jung J.H., Kim K., An I.S., Kim S.Y., Lee J.H., Park I.C., Jin Y.W., Lee S.J., An S. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation. FEBS Lett. 2012, 586:3057-3063.
173. Jackson M.W., Lindstrom M.S., Berberich S.J. MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. J. Biol. Chem. 2001, 276:25336-25341.
174. Li M., Gu W. A critical role for noncoding 5S rRNA in regulating Mdmx stability. Mol. Cell 2011, 43:1023-1032.
175. Amson R., Pece S., Lespagnol A., Vyas R., Mazzarol G., Tosoni D., Colaluca I., Viale G., Rodrigues-Ferreira S., Wynendaele J., Chaloin O., Hoebeke J., Marine J.C., Di Fiore P.P., Telerman A. Reciprocal repression between P53 and TCTP. Nat. Med. 2012, 18:91-99.
176. Shi D., Pop M.S., Kulikov R., Love I.M., Kung A.L., Grossman S.R. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16275-16280.
177. Wu H., Pomeroy S.L., Ferreira M., Teider N., Mariani J., Nakayama K.I., Hatakeyama S., Tron V.A., Saltibus L.F., Spyracopoulos L., Leng R.P. UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat. Med. 2011, 17:347-355.
178. Kaneko-Oshikawa C., Nakagawa T., Yamada M., Yoshikawa H., Matsumoto M., Yada M., Hatakeyama S., Nakayama K., Nakayama K.I. Mammalian E4 is required for cardiac development and maintenance of the nervous system. Mol. Cell. Biol. 2005, 25:10953-10964.
179. Higashitsuji H., Higashitsuji H., Itoh K., Sakurai T., Nagao T., Sumitomo Y., Masuda T., Dawson S., Shimada Y., Mayer R.J., Fujita J. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer cell 2005, 8:75-87.
180. Sui G., Affar el B., Shi Y., Brignone C., Wall N.R., Yin P., Donohoe M., Luke M.P., Calvo D., Grossman S.R., Shi Y., Yang Yin 1 is a negative regulator of p53. Cell 2004, 117:859-872.
181. Lee J.S., Galvin K.M., See R.H., Eckner R., Livingston D., Moran E., Shi Y. Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300. Genes Dev. 1995, 9:1188-1198.
182. Mayo L.D., Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:11598-11603.
183. Ogawara Y., Kishishita S., Obata T., Isazawa Y., Suzuki T., Tanaka K., Masuyama N., Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 2002, 277:21843-21850.
184. Feng J., Tamaskovic R., Yang Z., Brazil D.P., Merlo A., Hess D., Hemmings B.A. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J. Biol. Chem. 2004, 279:35510-35517.
185. Lopez-Pajares V., Kim M.M., Yuan Z.M. Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding. J. Biol. Chem. 2008, 283:13707-13713.
186. Zwang Y., Sas-Chen A., Drier Y., Shay T., Avraham R., Lauriola M., Shema E., Lidor-Nili E., Jacob-Hirsch J., Amariglio N., Lu Y., Mills G.B., Rechavi G., Oren M., Domany E., Yarden Y. Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol. Cell 2011, 42:524-535.
187. Kulikov R., Boehme K.A., Blattner C. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol. Cell. Biol. 2005, 25:7170-7180.
188. Wang X.D., Morgan S.C., Loeken M.R. Pax3 stimulates p53 ubiquitination and degradation independent of transcription. PLoS One 2011, 6:e29379.
189. Piccinin S., Tonin E., Sessa S., Demontis S., Rossi S., Pecciarini L., Zanatta L., Pivetta F., Grizzo A., Sonego M., Rosano C., Dei Tos A.P., Doglioni C., Maestro R. A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation. Cancer cell 2012, 22:404-415.
190. Ji H., Ding Z., Hawke D., Xing D., Jiang B.H., Mills G.B., Lu Z. AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis. EMBO Rep. 2012, 13:554-560.
191. Nie J., Xie P., Liu L., Xing G., Chang Z., Yin Y., Tian C., He F., Zhang L. Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2. J. Biol. Chem. 2010, 285:22818-22830.
192. Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J., Jung S.Y., O'Malley B.W., Gu W., Qin J., Wang Y. RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4579-4584.
193. Shloush J., Vlassov J.E., Engson I., Duan S., Saridakis V., Dhe-Paganon S., Raught B., Sheng Y., Arrowsmith C.H. Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2. J. Biol. Chem. 2011, 286:4796-4808.
194. Tang Y., Zhao W., Chen Y., Zhao Y., Gu W. Acetylation is indispensable for p53 activation. Cell 2008, 133:612-626.
195. Hakem A., Bohgaki M., Lemmers B., Tai E., Salmena L., Matysiak-Zablocki E., Jung Y.S., Karaskova J., Kaustov L., Duan S., Madore J., Boutros P., Sheng Y., Chesi M., Bergsagel P.L., Perez-Ordonez B., Mes-Masson A.M., Penn L., Squire J., Chen X., Jurisica I., Arrowsmith C., Sanchez O., Benchimol S., Hakem R. Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet. 2011, 7:e1002360.
196. Chen D., Kon N., Li M., Zhang W., Qin J., Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005, 121:1071-1083.
197. Kon N., Zhong J., Qiang L., Accili D., Gu W. Inactivation of arf-bp1 induces p53 activation and diabetic phenotypes in mice. J. Biol. Chem. 2012, 287:5102-5111.
198. Esser C., Scheffner M., Hohfeld J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J. Biol. Chem. 2005, 280:27443-27448.
199. Naito A.T., Okada S., Minamino T., Iwanaga K., Liu M.L., Sumida T., Nomura S., Sahara N., Mizoroki T., Takashima A., Akazawa H., Nagai T., Shiojima I., Komuro I. Promotion of CHIP-mediated p53 degradation protects the heart from ischemic injury. Circ. Res. 2010, 106:1692-1702.
200. Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J., Bergmann A., Johnson R.L., Barton M.C. Trim24 targets endogenous p53 for degradation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:11612-11616.
201. Momand J., Villegas A., Belyi V.A. The evolution of MDM2 family genes. Gene 2011, 486:23-30.
202. Jain A.K., Allton K., Iacovino M., Mahen E., Milczarek R.J., Zwaka T.P., Kyba M., Barton M.C. p53 regulates cell cycle and microRNAs to promote differentiation of human embryonic stem cells. PLoS Biol. 2012, 10:e1001268.
203. Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J., Schneider C., Del Sal G. p53 is involved in the p120E4F-mediated growth arrest. Oncogene 2000, 19:188-199.
204. Le Cam L., Linares L.K., Paul C., Julien E., Lacroix M., Hatchi E., Triboulet R., Bossis G., Shmueli A., Rodriguez M.S., Coux O., Sardet C. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 2006, 127:775-788.
205. Lacroix M., Caramel J., Goguet-Rubio P., Linares L.K., Estrach S., Hatchi E., Rodier G., Lledo G., de Bettignies C., Thepot A., Deraison C., Chebli K., Hovnanian A., Hainaut P., Dubus P., Sardet C., Le Cam L. Transcription factor E4F1 is essential for epidermal stem cell maintenance and skin homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21076-21081.
206. Laine A., Ronai Z. Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene 2007, 26:1477-1483.
207. Kruse J.P., Gu W. MSL2 promotes Mdm2-independent cytoplasmic localization of p53. J. Biol. Chem. 2009, 284:3250-3263.
208. Jung J.H., Bae S., Lee J.Y., Woo S.R., Cha H.J., Yoon Y., Suh K.S., Lee S.J., Park I.C., Jin Y.W., Lee K.H., An S., Lee J.H. E3 ubiquitin ligase Hades negatively regulates the exonuclear function of p53. Cell Death Differ. 2011, 18:1865-1875.
209. Laine A., Topisirovic I., Zhai D., Reed J.C., Borden K.L., Ronai Z. Regulation of p53 localization and activity by Ubc13. Mol. Cell. Biol. 2006, 26:8901-8913.
210. Yang W., Rozan L.M., McDonald E.R., Navaraj A., Liu J.J., Matthew E.M., Wang W., Dicker D.T., El-Deiry W.S. CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J. Biol. Chem. 2007, 282:3273-3281.
211. Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T., Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K., Yoo E., Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S., Eguchi K., Komiya S., Maruyama I., Higashi N., Sato M., Senoo H., Ochi T., Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A., Nishioka K., Tanaka K., Nakajima T. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J. 2007, 26:113-122.
212. Rajendra R., Malegaonkar D., Pungaliya P., Marshall H., Rasheed Z., Brownell J., Liu L.F., Lutzker S., Saleem A., Rubin E.H. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J. Biol. Chem. 2004, 279:36440-36444.
213. Migliorini D., Bogaerts S., Defever D., Vyas R., Denecker G., Radaelli E., Zwolinska A., Depaepe V., Hochepied T., Skarnes W.C., Marine J.C. Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J. Clin. Invest. 2011, 121:1329-1343.
214. Doyle J.M., Gao J., Wang J., Yang M., Potts P.R. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol. Cell 2010, 39:963-974.
215. Zhang L., Huang N.J., Chen C., Tang W., Kornbluth S. Ubiquitylation of p53 by the APC/C inhibitor Trim39. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:20931-20936.
216. Lee J., Zhou P. Cullins and cancer. Genes Cancer 2010, 1:690-699.
217. Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y., Li R., Yao X., Yi X., Shang Y. JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 regulation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:10195-10200.
218. Sato Y., Kamura T., Shirata N., Murata T., Kudoh A., Iwahori S., Nakayama S., Isomura H., Nishiyama Y., Tsurumi T. Degradation of phosphorylated p53 by viral protein-ECS E3 ligase complex. PLoS Pathog. 2009, 5:e1000530.
219. Nag A., Bagchi S., Raychaudhuri P. Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res. 2004, 64:8152-8155.
220. Kopanja D., Stoyanova T., Okur M.N., Huang E., Bagchi S., Raychaudhuri P. Proliferation defects and genome instability in cells lacking Cul4A. Oncogene 2009, 28:2456-2465.
221. Querido E., Blanchette P., Yan Q., Kamura T., Morrison M., Boivin D., Kaelin W.G., Conaway R.C., Conaway J.W., Branton P.E. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 2001, 15:3104-3117.
222. Luo K., Ehrlich E., Xiao Z., Zhang W., Ketner G., Yu X.F. Adenovirus E4orf6 assembles with Cullin5-ElonginB-ElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53. FASEB J. 2007, 21:1742-1750.
223. Andrews P., He Y.J., Xiong Y. Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function. Oncogene 2006, 25:4534-4548.
224. Verma S., Ali A., Arora S., Banerjea A.C. Inhibition of beta-TrcP-dependent ubiquitination of p53 by HIV-1 Vpu promotes p53-mediated apoptosis in human T cells. Blood 2011, 117:6600-6607.
225. Hu R., Aplin A.E. Skp2 regulates G2/M progression in a p53-dependent manner. Mol. Biol. Cell 2008, 19:4602-4610.
226. Banks D., Wu M., Higa L.A., Gavrilova N., Quan J.M., Ye T., Kobayashi R., Sun H., Zhang H. L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes. Cell Cycle 2006, 5:1719-1729.
227. Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 2010, 140:384-396.
228. Hock A.K., Vigneron A.M., Carter S., Ludwig R.L., Vousden K.H. Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J. 2011, 30:4921-4930.
229. Liu J., Chung H.J., Vogt M., Jin Y., Malide D., He L., Dundr M., Levens D. JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J. 2011, 30:846-858.
230. Sun X.X., Challagundla K.B., Dai M.S. Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1. EMBO J. 2012, 31:576-592.
231. Inuzuka H., Tseng A., Gao D., Zhai B., Zhang Q., Shaik S., Wan L., Ang X.L., Mock C., Yin H., Stommel J.M., Gygi S., Lahav G., Asara J., Xiao Z.X., Kaelin W.G., Harper J.W., Wei W. Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer cell 2010, 18:147-159.
232. Joo H.M., Kim J.Y., Jeong J.B., Seong K.M., Nam S.Y., Yang K.H., Kim C.S., Kim H.S., Jeong M., An S., Jin Y.W. Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and MDM2. Eur. J. Cell Biol. 2011, 90:420-431.
233. Li M., Chen D., Shiloh A., Luo J., Nikolaev A.Y., Qin J., Gu W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002, 416:648-653.
234. Cummins J.M., Vogelstein B. HAUSP is required for p53 destabilization. Cell Cycle 2004, 3:689-692.
235. Meulmeester E., Maurice M.M., Boutell C., Teunisse A.F., Ovaa H., Abraham T.E., Dirks R.W., Jochemsen A.G. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol. Cell 2005, 18:565-576.
236. Khoronenkova S.V., Dianova I.I., Ternette N., Kessler B.M., Parsons J.L., Dianov G.L. ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Mol. Cell 2012, 45:801-813.
237. Kon N., Kobayashi Y., Li M., Brooks C.L., Ludwig T., Gu W. Inactivation of HAUSP in vivo modulates p53 function. Oncogene 2010, 29:1270-1279.
238. Stevenson L.F., Sparks A., Allende-Vega N., Xirodimas D.P., Lane D.P., Saville M.K. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J. 2007, 26:976-986.
239. Kim J., Keay S.K., You S., Loda M., Freeman M.R. A synthetic form of frizzled 8-associated antiproliferative factor enhances p53 stability through USP2a and MDM2. PLoS One 2012, 7:e50392.
240. Allende-Vega N., Sparks A., Lane D.P., Saville M.K. MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene 2010, 29:432-441.
241. Zhang X., Berger F.G., Yang J., Lu X. USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1. EMBO J. 2011, 30:2177-2189.
242. Zhang J., Sun Q., Zhang Z., Ge S., Han Z.G., Chen W.T. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene 2013, 32:61-69.
243. Xiao J., Lin H., Luo X., Luo X., Wang Z. miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J. 2011, 30:524-532.
244. Suh S.S., Yoo J.Y., Nuovo G.J., Jeon Y.J., Kim S., Lee T.J., Kim T., Bakacs A., Alder H., Kaur B., Aqeilan R.I., Pichiorri F., Croce C.M. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:5316-5321.
245. Martins C.P., Brown-Swigart L., Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127:1323-1334.
246. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
247. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
248. Lujambio A., Akkari L., Simon J., Grace D., Tschaharganeh D.F., Bolden J.E., Zhao Z., Thapar V., Joyce J.A., Krizhanovsky V., Lowe S.W. Non-cell-autonomous tumor suppression by p53. Cell 2013, 449-460.
249. Reifenberger G., Liu L., Ichimura K., Schmidt E.E., Collins V.P. Amplification and overexpression of the Mdm2 gene in a subset of human-malignant gliomas without P53 mutations. Cancer Res. 1993, 53:2736-2739.
250. Riemenschneider M.J., Buschges R., Wolter M., Reifenberger J., Bostrom J., Kraus J.A., Schlegel U., Reifenberger G. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res. 1999, 59:6091-6096.
251. Wade M., Li Y.C., Wahl G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 2013, 83-96.
252. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
253. Hasegawa H., Yamada Y., Iha H., Tsukasaki K., Nagai K., Atogami S., Sugahara K., Tsuruda K., Ishizaki A., Kamihira S. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia 2009, 23:2090-2101.
254. La-Roche H. A study of R7112 in patients with hematologic neoplasms in:. http://clinicaltrials.gov/show/NCT00623870.
255. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., Pramanik A., Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 2004, 10:1321-1328.
256. Reed D., Shen Y., Shelat A.A., Arnold L.A., Ferreira A.M., Zhu F., Mills N., Smithson D.C., Regni C.A., Bashford D., Cicero S.A., Schulman B.A., Jochemsen A.G., Guy R.K., Dyer M.A. Identification and characterization of the first small molecule inhibitor of MDMX. J. Biol. Chem. 2010, 285:10786-10796.
257. Yang Y., Ludwig R.L., Jensen J.P., Pierre S.A., Medaglia M.V., Davydov I.V., Safiran Y.J., Oberoi P., Kenten J.H., Phillips A.C., Weissman A.M., Vousden K.H. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer cell 2005, 7:547-559.
258. Herman A.G., Hayano M., Poyurovsky M.V., Shimada K., Skouta R., Prives C., Stockwell B.R. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov. 2011, 1:312-325.
259. Roxburgh P., Hock A.K., Dickens M.P., Mezna M., Fischer P.M., Vousden K.H. Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis 2012, 33:791-798.
260. Graves B., Thompson T., Xia M., Janson C., Lukacs C., Deo D., Di Lello P., Fry D., Garvie C., Huang K.S., Gao L., Tovar C., Lovey A., Wanner J., Vassilev L.T. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:11788-11793.
261. Bernal F., Tyler A.F., Korsmeyer S.J., Walensky L.D., Verdine G.L. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J. Am. Chem. Soc. 2007, 129:2456-2457.
262. Baek S., Kutchukian P.S., Verdine G.L., Huber R., Holak T.A., Lee K.W., Popowicz G.M. Structure of the stapled p53 peptide bound to Mdm2. J. Am. Chem. Soc. 2012, 134:103-106.
263. Bernal F., Wade M., Godes M., Davis T.N., Whitehead D.G., Kung A.L., Wahl G.M., Walensky L.D. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer cell 2010, 18:411-422.
264. Brown C.J., Quah S.T., Jong J., Goh A.M., Chiam P.C., Khoo K.H., Choong M.L., Lee M.A., Yurlova L., Zolghadr K., Joseph T.L., Verma C.S., Lane D.P. Stapled peptides with improved potency and specificity that activate p53. ACS Chem. Biol. 2012, 8:506-512.
265. Wang H., Ma X., Ren S., Buolamwini J.K., Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol. Cancer Ther. 2011, 10:69-79.
266. Carvajal D., Tovar C., Yang H., Vu B.T., Heimbrook D.C., Vassilev L.T. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005, 65:1918-1924.
267. Sur S., Pagliarini R., Bunz F., Rago C., Diaz L.A., Kinzler K.W., Vogelstein B., Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3964-3969.
268. Grossman S.R., Perez M., Kung A.L., Joseph M., Mansur C., Xiao Z.X., Kumar S., Howley P.M., Livingston D.M. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 1998, 2:405-415.
269. Topisirovic I., Gutierrez G.J., Chen M., Appella E., Borden K.L., Ronai Z.A. Control of p53 multimerization by Ubc13 is JNK-regulated. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12676-12681.
270. Wu H., Leng R.P. UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation. Cell Cycle 2011, 10:1912-1915.